Association of serum HIF-1α levels with coronary artery calcification in patients of non-dialysis chronic kidney disease.

Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE

Original Publication: London : Nature Publishing Group, copyright 2011-

Hypoxia-Inducible Factor 1, alpha Subunit*/blood ; Renal Insufficiency, Chronic*/blood ; Renal Insufficiency, Chronic*/complications ; Coronary Artery Disease*/blood ; Coronary Artery Disease*/complications ; Vascular Calcification*/blood; Humans ; Male ; Female ; Middle Aged ; Aged ; Risk Factors ; ROC Curve

Vascular calcification is the main cause of death in patients with chronic kidney disease (CKD). The study aims to investigate the risk factor affecting coronary artery calcification (CAC), and the relationship between serum hypoxia-inducible factor-1α (HIF-1α) levels and CAC in non-dialysis CKD patients. One hundred and twenty-three patients were selected in the final analysis. Spearman rank correlation analysis assessed the correlation between HIF-1α levels and CAC scores. Logistic regression analysis was utilized to assess potential risk variables associated with CAC. A ROC curve was drawn to analyze the diagnostic value of HIF-1α in non-dialysis CKD patients with CAC. Compared to the non-CAC group, the CAC group was older age, with a higher proportion of males, smokers, hypertension and diabetes, lower eGFR and HDL-C, and higher SBP and HIF-1α levels. As the HIF-1α levels went up, the proportion of patients with VC increased, as well as Agatston scores. Spearman rank correlation analysis showed that HIF-1α levels were positively correlated with VC and Agatston scores. Logistic regression analysis indicated that being male (OR = 0.242, P = 0.036), older age (OR = 1.093, P < 0.001), and increased HIF-1α levels (OR = 1.002, P = 0.025) were risk factors for the occurrence of CAC. Furthermore, ROC curve analysis determined that a HIF-1α cutoff value of 451.177 pg·mL ^-1 provided the best diagnostic value for non-dialysis CAC, with a sensitivity of 65.8% and a specificity of 80.9%. The prevalence of CAC is high in non-dialysis CKD patients, with old age and male gender being traditional risk factors for CAC occurrence. HIF-1α positively correlate with both CAC and VC, which can provide certain diagnostic values for non-dialysis CAC.
Competing Interests: Competing interests: The authors declare no competing interests.
(© 2024. The Author(s).)

Lancet. 2010 Jun 12;375(9731):2073-81. (PMID: 20483451)
Sci Rep. 2022 Jan 13;12(1):682. (PMID: 35027586)
J Mol Med (Berl). 2021 Mar;99(3):335-348. (PMID: 33481059)
J Cell Physiol. 2024 May;239(5):e31211. (PMID: 38304971)
J Am Soc Hypertens. 2015 Dec;9(12):993-1000. (PMID: 26489731)
Atherosclerosis. 2016 Nov;254:249-253. (PMID: 27594539)
J Am Coll Cardiol. 1990 Mar 15;15(4):827-32. (PMID: 2407762)
Kidney Int. 2006 Jul;70(1):218-24. (PMID: 16723988)
Hypertension. 2006 Mar;47(3):410-4. (PMID: 16446387)
Exp Cell Res. 2016 Jul 15;345(2):206-17. (PMID: 27321958)
Front Cardiovasc Med. 2023 Jun 02;10:1168339. (PMID: 37332579)
N Engl J Med. 2007 Jun 21;356(25):2591-602. (PMID: 17582069)
J Am Soc Nephrol. 2005 Feb;16(2):507-13. (PMID: 15601745)
Circulation. 2003 Oct 28;108(17):2154-69. (PMID: 14581387)
Toxins (Basel). 2020 Jan 19;12(1):. (PMID: 31963891)
Int J Mol Sci. 2019 Nov 25;20(23):. (PMID: 31775364)
Eur Radiol. 2023 Jul;33(7):4723-4733. (PMID: 36705681)
Endocrine. 2017 Jan;55(1):130-138. (PMID: 27522360)
J Cardiovasc Comput Tomogr. 2019 Jan - Feb;13(1):41-47. (PMID: 30297127)
J Am Coll Cardiol. 2019 Oct 8;74(14):1823-1838. (PMID: 31582143)
J Atheroscler Thromb. 2024 Jan 1;31(1):1-14. (PMID: 37766573)
Biomedicines. 2021 Apr 24;9(5):. (PMID: 33923349)
Lancet. 2012 Sep 1;380(9844):807-14. (PMID: 22717317)
Kidney Dis (Basel). 2022 Jan 14;8(2):103-114. (PMID: 35527989)
Int J Mol Sci. 2022 Sep 23;23(19):. (PMID: 36232501)
Front Cell Dev Biol. 2021 Mar 16;9:611922. (PMID: 33816463)
Int Urol Nephrol. 2012 Aug;44(4):1269-76. (PMID: 22648290)
Arterioscler Thromb Vasc Biol. 2019 Jun;39(6):1088-1099. (PMID: 31070451)
Lancet. 2020 Feb 29;395(10225):709-733. (PMID: 32061315)
Ann Intern Med. 2009 May 5;150(9):604-12. (PMID: 19414839)
JAMA Cardiol. 2017 Jun 1;2(6):635-643. (PMID: 28329057)
Cardiovasc Diabetol. 2014 Feb 24;13:52. (PMID: 24564828)
Expert Opin Ther Targets. 2016;20(1):89-105. (PMID: 26788590)
Sci Rep. 2018 Sep 13;8(1):13730. (PMID: 30213959)
Nephrol Dial Transplant. 2023 May 4;38(5):1227-1239. (PMID: 36066908)
J Am Soc Nephrol. 2022 Aug;33(8):1590-1601. (PMID: 35654602)
Vascular. 2020 Aug;28(4):465-474. (PMID: 32089109)
Adv Clin Chem. 2020;98:91-147. (PMID: 32564789)
Ren Fail. 2019 Nov;41(1):244-256. (PMID: 31014155)

20211515 Health Commission of Hebei Province

Keywords: Coronary artery calcification; Gender; Hypoxia-inducible factor-1α; Non-dialysis chronic kidney disease; Prolyl hydroxylase inhibitor

0 (Hypoxia-Inducible Factor 1, alpha Subunit)
0 (HIF1A protein, human)

Date Created: 20241123 Date Completed: 20241123 Latest Revision: 20241126

20241202

PMC11585538

10.1038/s41598-024-79393-0

39580489